Rivanicline Uses, Dosage, Side Effects and more
Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release.
| Attribute | Details |
|---|---|
| Trade Name | Rivanicline |
| Generic | Rivanicline |
| Rivanicline Other Names | (E)-metanicotine, Rivanicline, trans-metanicotine |
| Type | |
| Formula | C10H14N2 |
| Weight | Average: 162.2316 Monoisotopic: 162.115698458 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in ulcerative colitis.
How Rivanicline works
Rivanicline is a (E)-metanicotine hemigalactarate. It effectively inhibits TNF- and LPS-induced IL-8 production in different cell types.
